anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
COAGADEX is a plasma-derived, sterile, purified concentrate of human coagulation Factor X that contains sucrose as a stabilizer. It is formulated as a lyophilized powder for solution for intravenous administration. When reconstituted with Sterile Water for Injection it forms a colorless, clear or slightly pearl-like solution. COAGADEX contains nominally (approximately) 100 IU/mL of coagulation Factor X and the following inactive ingredients: chloride, phosphate, citrate, sucrose and sodium. Each vial of COAGADEX is labeled with the actual Factor X activity/content expressed in IU per vial. Factor X activity in IU is determined using an in vitro chromogenic assay and a Factor X concentrate reference standard calibrated against the current WHO International Standard for Blood Coagulation Factors II and X Concentrate.

COAGADEX contains no added biological components such as heparin, albumin or anti-thrombin. The content of Factor II and Factor IX are ≤ 1 IU/mL of the reconstituted product. Factor Xa and Factor IIa were not detectable by Non-activated Partial Thromboplastin Time (NaPTT) or Fibrinogen Clotting Time (FCT) tests for potential thrombogenicity, and comprised < 10 parts per million by weight when tested by more sensitive analytical methods. The specific activity of COAGADEX is typically 80-137 IU per mg protein. The product contains no preservatives.

COAGADEX is manufactured from plasma, obtained from healthy US donors, who have passed viral screening tests. All donors are subjected to medical examinations, laboratory tests, and a review of their medical history before being allowed to donate blood or plasma.

All plasma donations are screened for antibody to human immunodeficiency virus (HIV)-1/2, hepatitis C virus (HCV), and hepatitis B surface antigen (HBsAg). Additional testing of donations is carried out in plasma mini-pools (512 donations per pool) with nucleic acid amplification testing (NAT) for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis A virus (HAV) and human parvovirus B19. Furthermore, each manufacturing pool is tested to be negative for HBsAg and anti-HIV-1/2 antibodies. Also, manufacturing pools are non-reactive by nucleic acid test for HAV, HBV, HCV, and HIV-1. The limit for human parvovirus B19 in the manufacturing pools is set not to exceed 104 IU/mL.

Three processing steps specifically designed to remove or inactivate viruses are:

1) Solvent/detergent treatment targeted to inactivate enveloped viruses

2) A 15-nm filtration step designed to remove small viruses including non-enveloped viruses

3) Terminal dry-heat treatment at 80°C for 72 hours in the final container to inactivate enveloped and non-enveloped viruses

The capacity of the manufacturing process to remove and/or inactivate enveloped and non-enveloped viruses has been validated by laboratory spiking studies on a scaled-down process model. Overall virus reduction was calculated only from steps that were mechanistically independent from each other. Table 2 presents the contribution of each process step to virus reduction and the overall process reduction.
FIELD: organic chemistry, medicine, endocrinology. SUBSTANCE: invention relates to 5-[4-(6-methoxy- 1-methyl-1H-benzimidazole-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione hydrochloride. The medicinal agent eliciting hypoglycemic activity contains the claimed compound as an active component and usual addition. Invention relates also to method for prophylaxis or treatment of hyperglycemia, diabetes mellitus and reduced tolerance to glucose in mammal by administration of 5-[4-(6-methoxy-1-methyl-1H- benzimidazole-2-ylmethoxy)benzyl[-thiazolidine-2,4-dione hydrochloride in effective dose. Invention relates also to method for improvement of states in insulin resistance in mammals by administration of the claimed agent in effective dose. Invention provides preparing the novel compound eliciting hypoglycemic activity. EFFECT: valuable medicinal property of compound. 14 cl, 2 tbl, 2 dwg, 2 ex
PURPOSE:To obtain a poly-gamma-glutamic acid which is a sale high polymer for carrying a medicine capable of retaining pharmacodynamic effects for a long time. CONSTITUTION:A poly-gamma-glutamic acid (hereinafter referred to as gamma-PGA) expressed by the formula [(n) is positive integer] or its salt is obtained by polymerizing an amino group of glutamic acid with a gamma-carboxyl group thereof by formation of peptide bond and has high accumulating property to cancer tissue and is excellent in sustained release property of medicine and exhibits biodegradability. A carcinostatic agent (e.g. 5-fluorouracil) is carried through a chemical bond such as ester bond or amide bond onto gamma-PGA and the medicine is fed to a cancer tissue. A carcinostatic agent carried on gamma-PGA sustains carcinostatic action for a long period by gradually hydrolyzing the ester bond, etc. The dose of the medicinal composition containing gamma-PGA as a main ingredient is 50-1500mg/adult daily.
BACKGROUND: Cancer-associated fibroblasts (CAFs) and their secretion, C-X-C motif chemokine ligand 12 (CXCL12), play an important role in the development of lung adenocarcinoma (LUAD). Interleukin 17A (IL-17A) is also crucial in regulating tumor progression. Herein, we explored the specific relationships between these two factors and their mechanisms in the progression of LUAD.
METHODS: Immunohistochemistry was utilized to assess the differential expression levels of IL-17A and CXCL12 in tumor versus normal tissues of LUAD patients, followed by gene correlation analysis. Cell counting kit-8 (CCK8), wound-healing and transwell assays were performed to investigate the effect of IL-17A on the function of LUAD cells. qPCR, immunofluorescence, immunohistochemistry and western blot analyses were conducted to elucidate the potential mechanism by which IL-17A facilitates the development of LUAD via CXCL12. Male BALB-C nude mice were used to explore the role of IL-17A in subcutaneous LUAD mouse models.
RESULTS: Elevated expression levels of IL-17A and CXCL12 were observed in LUAD tissues, exhibiting a positive correlation. Further studies revealed that IL-17A could stimulate CAFs to enhance the release of CXCL12, thereby facilitating the growth, proliferation, and metastasis of LUAD. The binding of CXCL12 to its specific receptor influences the activation of the Wnt/β-Catenin pathway, which in turn affects the progression of LUAD. In vivo experiments have demonstrated that IL-17A enhances the growth of LUAD tumors by facilitating the secretion of CXCL12. Conversely, inhibiting CXCL12 has been demonstrated to impede tumor growth.
CONCLUSIONS: We discovered that IL-17A promotes the release of CAFs-derived CXCL12, which in turn facilitates the development of LUAD via the Wnt/β-Catenin signaling pathway.
The treatment group implies patients with an acute cerebral disease ensured by CT, MRI or spinal tap. Pupillometry measurements are done during neurological routine examinations. Generally, during the initial diagnosis examination, followed by daily routine measurements and after 3 and 6 month upon hospital discharge.
Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.
Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator.

For adults, 4 drops of the suspension should be instilled into the affected ear 3 or 4 times daily.

For children, 3 drops are suggested because of the smaller capacity of the ear canal.

The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear.

If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further suspension every 4 hours. The wick should be replaced at least once every 24 hours.

SHAKE WELL BEFORE USING.
OBJECTIVE: To assess whether universal use of every-other-day glucose monitoring in patients with gestational diabetes mellitus (GDM) resulted in similar birth weights and medication use and was preferred by the patient compared with traditional daily glucose monitoring.
METHODS: This was a noninferiority randomized controlled trial conducted at a single New York City hospital between April 2021 and May 2022. Patients with singleton pregnancies who were diagnosed with GDM after 20 weeks of gestation and had a minimum of 7 days of previous daily blood glucose testing were randomly assigned to test blood glucose values daily or every other day. The primary outcome was neonatal birth weight. We calculated a total sample size of 196 participants needed for noninferiority to be tested, assuming the mean birth weight in the every-other-day group, compared with the daily group, was no higher than the predefined noninferiority margin of 200 g (80% power and one-sided alpha of 0.05). Postrandomization characteristics, including blood glucose values and medication initiation and timing, were recorded. Satisfaction with treatment group was assessed using the validated Oxford Maternity Diabetes Treatment Satisfaction Questionnaire.
RESULTS: A total of 197 patients were randomized: 98 in the daily group and 99 in the every-other-day group. Baseline characteristics were similar between groups. The mean neonatal birth weight was similar between groups (mean±SD 3,090±418 g among newborns in the daily group compared with 3,181±482 g among newborns in the every-other-day group). For the primary outcome, the every-other-day group was found to be noninferior to the daily group with an upper confidence limit for the mean difference in mean birth weight of 197 g, which was below the noninferiority margin of 200 g ( P =.046). Postrandomization, there were no significant differences in the number of patients who required medication, the gestational age at which medication was started, or the type of medication used. Average fasting and postprandial glucose values were similar between groups. There was an increase in adherence to treatment group in those randomized to every-other-day blood sugars, but no difference in patient satisfaction.
CONCLUSION: In patients with GDM, testing blood glucose values every other day was as effective as testing daily, without apparent effects on birth weight, medication initiation, or glucose control. Reduced frequency of blood glucose monitoring might help decrease the emotional, physical, and financial burden experienced by patients with GDM.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT04857073.
Cured granulates having a cornified surface layer and in which denatured protein (albumin) content present 100% are used as a dietetic food in slimming diets and as substrates for coatings contg. esp. hepatotropic and/or vitamin-contg. and flavouring substances. Granulates (i) swell in stomach and do not dissolve for a long time and provide a prolonged feeling of satiety; (ii) sufficient protein is supplied for body metabolism; (iii) taste is neutral, prods. can be stored for unlimited periods and are easily swallowed; (iv) prod. is natural and non-toxic. Granulates are prepd. by (a) drying to 50% moisture content, e.g. by centrifuging or pressing; extrusion to 2 mm dia. strands, drying at 120 degrees C.
This invention concerns a method for recovering a purified eucaryotic growth hormone or an analog thereof from a bacterial cell in which the growth hormone or analog has been produced by means of expression of a DNA sequence encoding the hormone or analog. The method involves the following steps: (a) disrupting the cell wall of the bacterial cell or fragments thereof to produce a lysate (b) separating a precipitate containing particulate and insoluble material from the lysate (c) preparing suspension of the separated precipitate in an appropriate buffer solution (d) treating the suspension to effect contact between liquid and solids (e) separating partially or completely precipitated material from the liquid-solids contacted suspension (f) solubilizing the separated precipitate in a sufficient amount of water and adjusting the pH to a suitable alkaline pH to form a solution (g) separating the solubilized hormone or analog from other cellular components by ultrafiltration under suitable conditions to produce an ultrafiltrate containing the hormone or analog and a retentate, and (h) treating the solubilized hormone or analog so as to concentrate the hormone or analog and thereby recover purified hormone or analog. Separations may be effected by ultrafiltration or centrifugation. Sonication as well as the ultrafiltration in step (i) may be repeated. Additionally, most of the process steps may be performed in a continuous flow and may be automated. Suitable hormone-producing bacterial cells for use in this invention include genetically modified strains of Escherichia coli. Growth hormones which can be recovered and purified using this invention include bovine, porcine, chicken, and human growth hormones, and analogs thereof.
Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen, based on pre-dinner capillary blood glucose measurements (CPG) expressed in mg/dl; All NPH initiation doses and dose adjustments are presented in IU/day For pts. with CPG \> 240, NPH initiation: 14, dose increases by 4; For pts. with CPG \> 180 mg/dl, NPH initiation: 12, dose increases by 4; For pts. with CPG \> 140 mg/dl, NPH initiation: 10, dose increases by 4; For pts. with CPG \> 120 mg/dl, NPH initiation: 0, dose increases by 2; For pts. with CPG 100-119 mg/dl, NPH initiation: 0, maintain dose; For pts. with CPG 80-\<100 mg/dl, NPH initiation: 0, dose decrease by 4; For pts. with CPG 60-\<80 mg/dl, NPH initiation: 0, decrease by 8; For pts. with CPG \<60 mg/dl, NPH initiation: 0, ½ of previous dose.
BACKGROUND: In spite of its high mortality rate and poor prognosis, the pathogenesis of sepsis is still incompletely understood. This study established a cuproptosis-based risk model to diagnose and predict the risk of sepsis. In addition, the cuproptosis-related genes were identified for targeted therapy.
METHODS: Single-cell sequencing analyses were used to characterize the cuproptosis activity score (CuAS) and intercellular communications in sepsis. Differential cuproptosis-related genes (CRGs) were identified in conjunction with single-cell and bulk RNA sequencing. LASSO and Cox regression analyses were employed to develop a risk model. Three external cohorts were conducted to assess the model's accuracy. Differences in immune infiltration, immune cell subtypes, pathway enrichment, and the expression of immunomodulators were further evaluated in distinct groups. Finally, various in-vitro experiments, such as flow cytometry, Western blot, and ELISA, were used to explore the role of LST1 in sepsis.
RESULTS: ScRNA-seq analysis demonstrated that CuAS was highly enriched in monocytes and was closely related to the poor prognosis of sepsis patients. Patients with higher CuAS exhibited prominent strength and numbers of cell-cell interactions. A total of five CRGs were identified based on the LASSO and Cox regression analyses, and a CRG-based risk model was established. The lower riskScore cohort exhibited enhanced immune cell infiltration, elevated immune scores, and increased expression of immune modulators, indicating the activation of an antibacterial response. Ultimately, in-vitro experiments demonstrated that LST1, a key gene in the risk model, was enhanced in the macrophage in response to LPS, which was closely related to the decrease of macrophage survival rate, the enhancement of apoptosis and oxidative stress injury, and the imbalance of the M1/M2 phenotype.
CONCLUSIONS: This study constructed a cuproptosis-related risk model to accurately predict the prognosis of sepsis. We further characterized the cuproptosis-related gene LST1 to provide a theoretical framework for sepsis therapy.
Saxagliptin (trade-name ONGLYZA™) is used along with diet and exercise to lower blood sugar levels in patients with Type II diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin produced by the body after meals when blood sugar is high As the blood sugar returns towards normal, the medication effect on insulin is decreased.
Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
AIMS: Coronary computed tomography angiography (CTA) and fractional flow reserve by computed tomography (FFR-CT) are increasingly utilized to characterize coronary artery disease (CAD). We evaluated the feasibility of distal-vessel FFR-CT as an integrated measure of epicardial CAD that can be followed serially, assessed the CTA parameters that correlate with distal-vessel FFR-CT, and determined the combination of clinical and CTA parameters that best predict distal-vessel FFR-CT and distal-vessel FFR-CT changes.
METHODS AND RESULTS: Patients (n = 71) who underwent serial CTA scans at ≥2 years interval (median = 5.2 years) over a 14-year period were included in this retrospective study. Coronary arteries were analysed blindly using artificial intelligence-enabled quantitative coronary CTA. Two investigators jointly determined the anatomic location and corresponding distal-vessel FFR-CT values at CT1 and CT2. A total of 45.3% had no significant change, 27.8% an improvement, and 26.9% a worsening in distal-vessel FFR-CT at CT2. Stepwise multiple logistic regression analysis identified a four-parameter model consisting of stenosis diameter ratio, lumen volume, low density plaque volume, and age, that best predicted distal-vessel FFR-CT ≤ 0.80 with an area under the curve (AUC) = 0.820 at CT1 and AUC = 0.799 at CT2. Improvement of distal-vessel FFR-CT was captured by a decrease in high-risk plaque and increases in lumen volume and remodelling index (AUC = 0.865), whereas increases in stenosis diameter ratio, medium density calcified plaque volume, and total cholesterol presaged worsening of distal-vessel FFR-CT (AUC = 0.707).
CONCLUSION: Distal-vessel FFR-CT permits the integrative assessment of epicardial atherosclerotic plaque burden in a vessel-specific manner and can be followed serially to determine changes in global CAD.
Discloses a coated tablet composition for administration once daily comprising a coating and a tablet core. The coating comprises an immediate release part comprising one or more glucocorticoids and pharmaceutically acceptable release excipients or carriers adapted so that the one or more glucocorticoids are immediately released. The coating contains an amount of 20-40 % of the total hydrocortisone equivalents in the composition. The tablet core comprises an extended release part comprising one or more glucocorticoids in an amount of 60-80% of the total hydrocortisone equivalents in the composition and pharmaceutically acceptable extended release excipients or carriers adapted so that the one or more glucocorticoids are released over an extended period of time of at least about 8 hours. The total daily dose of the glucocorticoids is in the range 1-80 mg. Further disclosed are various embodiments of the composition that detail the amount of total hydrocortisone equivalents released in a given timeframe from either the immediate release part or the extended release part of the composition. Also disclosed is the use the coated tablet composition used in the preparation of a medicament for the treatment of a glucocorticoid deficiency associated disorder.
PURPOSE: To obtain a medicinal composition containing a phosphodiesterase inhibitor and a specific thromboxane A2 antagonist and effective in treating or preventing thromboembolic complication accompanying platelet action abnormality. CONSTITUTION: This new medicinal composition comprises a phosphodiesterase inhibitor [e.g. pyrimid[5,4-d]pyrimidine-based phosphodiesterase inhibitor] and a thromboxane A2 antagonist selected from a compound of formula I  R1 is phenyl which may be substituted by a substituent group such as hydrogen or methyl; R2 is hydroxycarbonyl, etc.] or formula II [R3 is phenyl, benzyl, nitrophenyl, etc., which may be substituted by a substituted group (e.g. a halogen or methyl); R4 is a (substituted)hydroxycarbonyl, etc.; X is an imino, O or S which may be substituted by a 1-3C alkyl group] and its acid addition salt. The composition is free from adverse effect caused by the combination and suitable for treating and preventing leg deep part venous thrombosis after operating heart valve or blood vessel.
Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter \> 7.0 cm or coronal maximal diameter \> 7.0 cm. In this cohort. Pts will receive 4 cycles of brentuximab vedotin \& AVD chemo. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 \& 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, \& Dacarbazine 375 mg/m2 will be administered on days 1 \& 15 of each 28 day cycle. Pts whose PET scan is negative after 4 cycles of brentuximab vedotin \& AVD chemotherapy will not receive RT. Pts whose PET scan is positive after 4 cycles of brentuximab vedotin \& AVD chemo, but subsequent biopsy is neg, will also receive no RT. Upon MSK PI approval, if the simulation can't be covered by the institution or the pts insurance, a diagnostic IV contrast CT neck \& diagnostic IV contrast CT CAP scan will be done in addition to the FDG-PET done after 4 cycles of chemo.
Omeprazole and sodium bicarbonate capsule is a combination of omeprazole, a proton-pump inhibitor, and sodium bicarbonate, an antacid. Omeprazole is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, a racemic mixture of two enantiomers that inhibits gastric acid secretion. Its molecular formula is C17H19N3O3S, with a molecular weight of 345.42. The structural formula is: 

Omeprazole, USP is a white to off-white powder. It melts between 150 C and 160 C, with decomposition. It is soluble in dichloromethane; sparingly soluble in methanol and in alcohol.

Each omeprazole and sodium bicarbonate capsule intended for oral administration contains omeprazole, 20 mg or 40 mg and sodium bicarbonate, 1100 mg. In addition, each capsule contains the following inactive ingredients: croscarmellose sodium, gelatin, sodium lauryl sulphate, sodium stearyl fumarate and titanium dioxide. The capsule shell is printed with black pharmaceutical ink which contains following ingredients: black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac and strong ammonia solution.